CYP2B6 基因多态性与氯吡格雷在轻型卒中或短暂性脑缺血发作中疗效的关联
基于 CHANCE 随机临床试验的事后分析,对 2853 例中国轻型卒中或短暂性脑缺血发作患者进行 CYP2B6-516G>T 和 -1456T>C 基因分型,比较阿司匹林联合氯吡格雷与单用阿司匹林的疗效。结果显示,在携带者与非携带者之间,联合治疗相对单用阿司匹林对 90 天新发卒中的疗效无显著差异(交互作用 P=0.29)。作者认为携带者和非携带者均可能从联合治疗中获益。
要点
- CYP2B6-516 GT/TT 或 -1456 TC/CC 携带者占 32.8%。
- 非携带者 90 天新发卒中:联合组 7.1% vs 单药组 11.3%,校正 HR 0.61(95%CI 0.45-0.83)。
- 携带者 90 天新发卒中:联合组 9.7% vs 单药组 12.2%,校正 HR 0.80(95%CI 0.54-1.18),交互作用 P=0.29。
核心结论
- 在 CHANCE 试验的事后分析中,未观察到 CYP2B6-516 GT/TT 或 -1456 TC/CC 携带者与非携带者之间,阿司匹林联合氯吡格雷相对单用阿司匹林的疗效存在显著差异。
- 作者认为,携带者和非携带者的轻型卒中患者均可能从阿司匹林联合氯吡格雷治疗中获益,优于单用阿司匹林。
研究设计与样本
- 基于 CHANCE 随机临床试验(阿司匹林联合氯吡格雷 vs 单用阿司匹林)的事后分析。
- 2009 年 10 月至 2012 年 7 月在中国纳入轻型卒中或短暂性脑缺血发作患者,共 2853 例成功进行 CYP2B6-516G>T(rs3745274)和 CYP2B6-1456T>C(rs2054675)基因分型。
- 主要疗效和安全结局为 90 天内新发卒中和任何出血。
主要发现
- 2853 例患者中,32.8% 为 CYP2B6-516 GT/TT 或 -1456 TC/CC 基因型携带者。
- 非携带者 90 天新发卒中发生率:阿司匹林联合氯吡格雷组 7.1% vs 单用阿司匹林组 11.3%,校正 HR 0.61(95%CI 0.45-0.83)。
- 携带者 90 天新发卒中发生率:联合组 9.7% vs 单药组 12.2%,校正 HR 0.80(95%CI 0.54-1.18),交互作用 P=0.29。
- 非携带者 90 天任何出血发生率:联合组 2.2%(21 例出血) vs 单药组 1.9%(18 例出血),校正 HR 1.11(95%CI 0.59-2.09)。
- 携带者 90 天任何出血发生率:联合组 1.9%(9 例出血) vs 单药组 0.7%(3 例出血),校正 HR 3.23(95%CI 0.86-12.12);1 年随访结果相似。
临床怎么用
- 作者认为,携带者和非携带者的轻型卒中患者均可能从阿司匹林联合氯吡格雷治疗中获益,优于单用阿司匹林。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: CYP2B6 (cytochrome P450 subfamily IIB polypeptide 6), encoded by the CYP2B6 gene, is a critical enzyme involved in clopidogrel metabolism. However, the association between CYP2B6 polymorphisms and the efficacy of clopidogrel in minor stroke or transient ischemic attack for secondary stroke prevention remains unclear. METHODS: Based on CHANCE (Clopidogrel in High-Risk Patients With Acute Nondisabling Cerebrovascular Events) randomized clinical trial of aspirin plus clopidogrel versus aspirin alone, we investigated the role of CYP2B6 polymorphisms and the efficacy of clopidogrel in patients with minor stroke or transient ischemic attack in China from October 2009 to July 2012. A total of 2853 patients were successfully genotyped for CYP2B6-516G>T, rs3745274 and CYP2B6-1456 T>C, rs2054675. The primary efficacy and safety outcomes were new stroke and any bleeding within 90 days. RESULTS: Among the 2853 patients, 32.8% were identified as the carriers of the CYP2B6-516 GT/TT or -1456 TC/CC genotype. The incidences of 90-day new stroke in aspirin plus clopidogrel and aspirin alone groups were 7.1% versus 11.3% among noncarriers, respectively; and 9.7% versus 12.2% among carriers, respectively. The efficacy of aspirin plus clopidogrel versus aspirin alone was not significantly different (P interaction=0.29) in noncarriers (adjusted hazard ratio, 0.61 [95% CI, 0.45-0.83]) compared to carriers (adjusted hazard ratio, 0.80 [95% CI, 0.54-1.18]). The incidence (n=51) of 90-day any bleeding in aspirin plus clopidogrel and aspirin alone groups were 2.2% (21 bleeds) versus 1.9% (18 bleeds) among noncarriers (adjusted hazard ratio, 1.11 [95% CI, 0.59-2.09]) and 1.9% (9 bleeds) versus 0.7% (3 bleeds) among carriers (adjusted hazard ratio, 3.23 [95% CI, 0.86-12.12]). Similar findings were observed during the 1-year follow-up. CONCLUSIONS: In this post hoc analysis of the CHANCE trial, we did not observe a significant difference in the efficacy of aspirin plus clopidogrel compared with aspirin in carriers versus noncarriers of CYP2B6-516 GT/TT or -1456 TC/CC genotype. Our results suggest that both carriers and noncarriers suffering from a minor stroke are likely to benefit from aspirin plus clopidogrel treatment over aspirin monotherapy for secondary prevention. REGISTRATION: URL: https://www. CLINICALTRIALS: gov; Unique identifier: NCT00979589.
引用
- Qiu X, Zhang Y, Gu H, et al. Association Between CYP2B6 Polymorphisms and Efficacy of Clopidogrel in Minor Stroke or Transient Ischemic Attack. Stroke. 2023. PMID: 37264909. doi:10.1161/STROKEAHA.122.040507
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。